(-0.03%) 5 476.75 points
(-0.07%) 38 791 points
(0.01%) 19 922 points
(0.35%) $80.61
(1.29%) $2.82
(0.22%) $2 334.20
(-0.19%) $29.34
(-0.18%) $969.20
(0.01%) $0.932
(-0.15%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...
Stats | |
---|---|
Šios dienos apimtis | 827 575 |
Vidutinė apimtis | 549 561 |
Rinkos kapitalizacija | 757.59M |
EPS | $-1.000 ( Q1 | 2024-05-08 ) |
Kita pelno data | ( $-1.500 ) 2024-08-05 |
Last Dividend | $0.0596 ( 2013-01-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.98 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0730 (0.26%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-12 | Sassine Andy | Sell | 50 000 | Common Stock |
2024-06-05 | Chivukula Pad | Sell | 114 | Common Stock |
2024-06-03 | Chivukula Pad | Sell | 26 000 | Common Stock |
2024-03-25 | Chivukula Pad | Sell | 17 435 | Common Stock |
2024-03-19 | Chivukula Pad | Sell | 8 565 | Common Stock |
INSIDER POWER |
---|
59.83 |
Last 97 transactions |
Buy: 2 180 134 | Sell: 1 123 086 |
Tūris Koreliacija
Arcturus Therapeutics Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
OZEM | 1 |
WSC | 0.882 |
AKYA | 0.87 |
REE | 0.869 |
ASUR | 0.867 |
DOMO | 0.866 |
CTSH | 0.864 |
CRBU | 0.863 |
BMEA | 0.861 |
ATHA | 0.86 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
MGX | -0.862 |
OMH | -0.859 |
AMRK | -0.856 |
HYMC | -0.844 |
NA | -0.841 |
ALCE | -0.84 |
NVNI | -0.84 |
ICUCW | -0.839 |
SGHT | -0.836 |
ABAT | -0.835 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Arcturus Therapeutics Koreliacija - Valiuta/Žaliavos
Arcturus Therapeutics Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $157.75M |
Bruto pelnas: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2023 |
Pajamos: | $157.75M |
Bruto pelnas: | $154.79M (98.13 %) |
EPS: | $-1.120 |
FY | 2022 |
Pajamos: | $205.76M |
Bruto pelnas: | $62.70M (30.48 %) |
EPS: | $0.350 |
FY | 2021 |
Pajamos: | $12.36M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-7.74 |
Financial Reports:
No articles found.
Arcturus Therapeutics Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0200 | 2012-03-06 |
Last Dividend | $0.0596 | 2013-01-08 |
Next Dividend | $0 | N/A |
Payout Date | 2013-01-15 | |
Next Payout Date | N/A | |
# dividends | 12 | -- |
Total Paid Out | $0.679 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.71 | -- |
Div. Sustainability Score | 2.87 | |
Div.Growth Potential Score | 1.035 | |
Div. Directional Score | 1.952 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0.119 | 0.23% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Jan 2013 | $0.0596 | 27 Dec 2012 | 08 Jan 2013 | 15 Jan 2013 |
04 Jan 2013 | $0.0596 | 27 Dec 2012 | 08 Jan 2013 | 15 Jan 2013 |
05 Dec 2012 | $0.0600 | 28 Nov 2012 | 30 Nov -0001 | 15 Dec 2012 |
06 Nov 2012 | $0.0600 | 26 Oct 2012 | 30 Nov -0001 | 15 Nov 2012 |
03 Oct 2012 | $0.0600 | 27 Sep 2012 | 30 Nov -0001 | 15 Oct 2012 |
05 Sep 2012 | $0.0600 | 01 Aug 2012 | 30 Nov -0001 | 15 Sep 2012 |
06 Aug 2012 | $0.0600 | 26 Jul 2012 | 30 Nov -0001 | 15 Aug 2012 |
03 Jul 2012 | $0.0600 | 27 Jun 2012 | 30 Nov -0001 | 15 Jul 2012 |
06 Jun 2012 | $0.0600 | 29 May 2012 | 30 Nov -0001 | 15 Jun 2012 |
04 May 2012 | $0.0600 | 27 Apr 2012 | 30 Nov -0001 | 15 May 2012 |
03 Apr 2012 | $0.0600 | 14 Mar 2012 | 30 Nov -0001 | 15 Apr 2012 |
06 Mar 2012 | $0.0200 | 02 Mar 2012 | 30 Nov -0001 | 15 Mar 2012 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.916 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -0.249 | 1.200 | -8.29 | -9.95 | [0 - 0.3] |
returnOnEquityTTM | -0.376 | 1.500 | -5.29 | -7.94 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.26 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.73 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.50 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0762 | -1.500 | 8.73 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -4 842.17 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.458 | 2.00 | 9.85 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.368 | 2.00 | 9.82 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.121 | -1.500 | 9.52 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.570 | 1.000 | 3.83 | 3.83 | [0.2 - 0.8] |
operatingProfitMarginTTM | -1.022 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.385 | 1.000 | 8.97 | 8.97 | [0.2 - 2] |
assetTurnoverTTM | 0.272 | 0.800 | -1.523 | -1.218 | [0.5 - 2] |
Total Score | 2.87 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -8.35 | 1.000 | -0.944 | 0 | [1 - 100] |
returnOnEquityTTM | -0.376 | 2.50 | -3.40 | -7.94 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.368 | 2.00 | 9.88 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.458 | 2.00 | 9.85 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.641 | 1.500 | -7.61 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.108 | 1.000 | 9.80 | 0 | [0.1 - 0.5] |
Total Score | 1.035 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.